Glaxosmithkline
Big Business |
Health & Pharma
5 Crescent Drive, Philadelphia, PA 19112
Recent News About Glaxosmithkline
View More
-
A drug company sued by the widow of a Chicago man, who killed himself after taking the generic form of the antidepressant Paxil, argues that the widow has launched a “frivolous," “topsy-turvy” and "unprecedented" effort to have a Chicago federal district judge override the U.S. Supreme Court and restore a $3 million verdict.
-
In the wake of the U.S. Supreme Court’s recent refusal to hear her case, the widow of a Chicago man, who killed himself after allegedly taking the generic form of the antidepressant Paxil, is trying to have a federal district judge restore her $3 million verdict against drugmaker GSK, because the company allegedly didn’t push federal regulators to revise the drug’s warning label.
-
A federal appeals court in Chicago could be tasked with taking another look at its previous decision undoing a jury verdict ordering drug maker GSK to pay $3 million to the widow of a Chicago lawyer who committed suicide after taking the generic equivalent of a widely prescribed antidepressant drug.
-
The U.S. Supreme Court is tackling the question of whether drug companies can be sued for not making their warning labels strong enough, even though the FDA controls the labels. But whether a forthcoming Supreme Court decision will affect a decision denying a $3 million judgment to the widow of a Chicago lawyer who committed suicide after taking the generic equivalent of Paxil remains unclear.
-
The thinking behind a Massachusetts ruling that brand-name manufacturers can he held liable for injuries suffered by patients who take generic versions of the drug those manufacturers innovate could have bearing in a case before a federal appeals court in Chicago.
-
About two weeks after a Chicago federal judge turned down its request for a new trial, pharmaceutical maker GlaxoSmithKline has formally appealed the judicial decisions the company has contended led to a jury improperly awarding $3 million to the widow of a Chicago lawyer who committed suicide by stepping in front of a train in Chicago’s Loop after taking a generic version of Paxil, an antidepressant developed by GSK.
-
Pharmaceutical maker GlaxoSmithKline will not get a chance to undo a jury’s verdict, finding it owes $3 million to the widow of a Chicago lawyer who committed suicide, allegedly after taking a generic equivalent of GSK’s anti-depressant drug, Paxil.
-
A Chicago federal jury shocked many observers by ordering drugmaker GlaxoSmithKline to pay $3 million to the widow of lawyer Stewart Dolin, who committed suicide in 2010 after taking a generic version of GSK's antidepressant Paxil. But legal observers believe the decision may have a short shelf life, as it could defy decades of case law on the concept of innovator liability.
-
Drug manufacturer GlaxoSmithKline is trying to get out from under a $3 million jury judgment, which blamed it for a Chicago lawyer’s suicide, saying a federal judge made multiple mistakes that hamstrung the manufacturer’s defense against the claim its labels failed to warn its anti-depressant drug Paxil and its generic equivalent can lead to suicide.
-
A Chicago federal judge has dismissed several. but not all of the claims against the maker of a testosterone boosting drug, advanced by several plaintiffs chosen as bellwethers in a class-action lawsuit brought by more than 2,000 plaintiffs from around the U.S. against multiple drug manufacturers, including Besins, AbbVie, Eli Lilly and GlaxoSmithKline.
-
A federal jury in Chicago has ordered pharmaceutical maker GlaxoSmithKline to pay $3 million to the widow of a Chicago lawyer who committed suicide by jumping in front of a train after taking a generic version of Paxil, an antidepressant developed by GSK, finding the drugmaker should be held responsible for his death, even though it didn’t make the actual medication the lawyer had been taking for about a week before he took his life.
-
A Georgia man is suing several drug makers, including GlaxoSmithKline and Auxilium, for alleged design defect, liability and negligence for injuries he suffered while taking testosterone drugs.
-
A trial continues this week in Chicago federal court over the question of how much blame should be shouldered by drugmaker GlaxoSmithKline for the death of a Chicago lawyer who committed suicide after taking a generic version of Paxil, an antidepressant developed by GSK. This week, a federal judge denied an attempt by GSK to abruptly end the weeks-long trial and secure a judgment in its favor.
-
This week, a Chicago federal court will empanel jurors to decide whether pharmaceutical maker GlaxoSmithKline should be made to pay the widow of a Chicago lawyer who committed suicide by jumping in front of a train after taking a generic version of Paxil, an antidepressant developed by GSK, because, the woman claims, the drug’s warning label, which was approved by federal regulators, did not contain enough information on suicide risk, misleading the doctor who prescribed it.
-
Drugmaker GlaxoSmithKline, a United Kingdom-based company whose U.S. operations are headquartered in Philadelphia, will need to face legal action in Cook County court over claims its drug, Paxil, caused birth defects, after an appeals court ruled local state courts have jurisdiction under Illinois law to preside over the lawsuits – even complaints brought by plaintiffs who have no significant connection to Illinois.
-
A federal judge has tossed, with leave to amend, the bulk of a federal racketeering and fraud class action brought by an Ohio-based health insurer against Abbvie and other makers of testosterone drugs, saying the insurer has not yet backed up with enough particularity its allegations the drugmakers invented the condition known as “low T,” and, through false marketing to doctors, patients and insurers alike, induced insurers and others to pay far more for the drugs to treat the condition.
